Last reviewed · How we verify
Lumefantrine-artemether and nevirapine — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Lumefantrine-artemether and nevirapine (Lumefantrine-artemether and nevirapine) — Makerere University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lumefantrine-artemether and nevirapine TARGET | Lumefantrine-artemether and nevirapine | Makerere University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lumefantrine-artemether and nevirapine CI watch — RSS
- Lumefantrine-artemether and nevirapine CI watch — Atom
- Lumefantrine-artemether and nevirapine CI watch — JSON
- Lumefantrine-artemether and nevirapine alone — RSS
Cite this brief
Drug Landscape (2026). Lumefantrine-artemether and nevirapine — Competitive Intelligence Brief. https://druglandscape.com/ci/lumefantrine-artemether-and-nevirapine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab